Optimizing Wearable Adherence In A Phase 3 Oncology Trial Through Real-Time Data Workflows

Long-term wearable monitoring only works if patients keep wearing the device, and in oncology trials, that’s easier said than done. In this case study, Ametris partnered with Johnson & Johnson Innovative Medicine to improve wearable adherence in the global Phase 3 LIBERTAS trial for a metastatic castration-sensitive prostate cancer (mCSPC) therapy. Actigraphy devices were used in this study for more than 12 months to continuously measure sleep quality and physical activity as objective proxies for hot flash burden.

By combining continuous actigraphy monitoring with data-driven engagement strategies, the study achieved sustained high-quality data capture in an older, high-burden patient population. The results show how proactive adherence management can reduce missing data, strengthen digital endpoints, and help sponsors unlock more reliable insights from wearable technologies in complex clinical trials.